Lilly Asia Ventures
Est. 2008
- HQ
- China
- Founded
- 2008
- Focus
- Healthtech · Life Sciences · Healthcare & Life Sciences
- Tracked deals
- 1
About
Lilly Asia Ventures is a biomedical venture capital firm that originated in 2008 as an Eli Lilly corporate venture subsidiary and later became an independent investment manager.
Strategies
Venture Capital
Focused strategy
Investment Focus
Sources
Profile sources
- roboticsintl.com — Healthtech, Life Sciences, Healthcare & Life Sciences
Investment Criteria
Investment Stages
Stages
Seed Growth Pre IPO Public
Investment Geographies
Primary Markets
China
Coverage
Country-focused Regions
Asia
Coverage is a guide only.
Location
Headquarters
China
Office Presence
No office countries recorded
Deals & Activity
Tracked Deals
1
Most common deal types
Series B (1)
Recent tracked deals
Khartis Therapeutics
Series B - 2026
Similar investors
Qiming Venture Partners
Qiming Venture Partners is a top-tier VC firm with outstanding reputation. With our exceptional investment performances, we have been widely recognized by investors from around the world.We have a reputation for being entrepreneur friendly.
YuanBio Venture Capital
YuanBio Venture Capital is a China-based healthcare venture capital firm investing in early- and growth-stage companies across biotechnology, medical devices, diagnostics and healthcare services.
HanKang Capital
Hankang Capital is a venture capital arm of Zhongjianxin Group focused on biomedicine and related healthcare fields, including medical equipment, diagnostics and medical services.
Hillhouse Capital Group
Hillhouse is a global investment firm that began investing in public equities, later added a private-equity strategy, and now invests across all stages of company life cycles.
Wattle Hill Capital
Wattle Hill RHC Fund is a specialist investment manager focused on private equity in the Australia and New Zealand region, delivering customised value-creating investment solutions for its global clients.
Headquartered in Sydney, with offices in Hong Kong and Beijing, Wattle Hill RHC is a private equity fund focused on investments in quality Australian businesses that offer products and services in demand by Chinese consumers. Wattle Hill RHC identifies leading enterprises that will benefit from China's economic growth and development then helps them prepare for and navigate Chinese market entry and expansion. Wattle Hill RHC is one of the only investment firms with a defined concurrent focus on the Chinese and Australian markets.
Wattle Hill RHC established its Australian fund in March 2016 with two of the largest insurance groups from China and Europe, as well as family-office investors from China's leading private e-commerce and FMCG companies. Wattle Hill RHC's Investment Committee includes one of Australia's most respected investors, Ashok Jacob of Ellerston Capital, and Sean Huang of Riverhead Capital, the private equity arm of Sunshine Insurance Group, one of China's largest privately-owned insurance groups with over 35 million direct policy holders.
Tembusu Partners
Tembusu Partners is a private equity firm based in Singapore with deep roots in Emerging Asia. We invest in growth capital and mezzanine debt opportunities in Emerging Asia, especially in China, India and Southeast Asia. We have a deep understanding of Asia's markets, investment cycles and complex cultural nuances grants us clarity and insight into regional economies. Our portfolio companies span diverse industries, ranging from education and healthcare to technology and oil & gas. These innovative enterprises are backed by an advisory board and investment committee of well-connected corporate leaders and industry experts, all of whom are dedicated to supporting high-growth business ventures and helping them flourish.
Other Asset Managers with Offices in China
#1 Blackstone
Blackstone is a global alternative asset manager investing across private equity, real estate, credit and insurance, multi-asset, secondaries, tactical opportunities, infrastructure, life sciences, growth and energy transition strategies.
#2 KKR
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate, credit and hedge funds. The firm is a recognised global leader in private equity, with a long history of successful investments dating back to its founding in 1976. Although originally specialising in leveraged buy-out (control) transactions, KKR today participates in almost every asset class.
#3 The Carlyle Group
The Carlyle Group is a global private equity and alternative asset manager headquartered in Washington DC, USA. Carlyle was founded in 1987 and has grown to become one of the largest, most well known and most respected private equity managers globally. Carlyle operates across four principal strategies: Corporate Private Equity ($75bn AUM), Real Estate and Infrastructure ($44bn AUM), Global Credit ($34bn) and Fund of Funds / Investment Solutions ($34bn AUM).
Carlyle was founded in 1987, originally as an investment banking boutique, by five founders: William Conway, Stephen Norris, David Rubenstein, Daniel D'Aniello and Greg Rosenbaum.
Carlyle went public through a NASDAQ listing in May 2012.
#4 EQT Partners
EQT Partners is a global alternative investment firm with strategies across private equity, infrastructure, real estate, growth equity, and public value.
#5 Oaktree Capital
Oaktree Capital is one of the world's leading alternative investment managers. Oaktree has its original roots in high yielding and distressed credit/debt, although today invests across the spectrum from equity to debt. There are four primary strategies: credit, private equity, real assets, and listed equities. Credit comprises approximately 70% of the portfolio, with private equity and real assets comprising most of the remainder. Oaktree has a strong culture and investment philosophy focused on risk control, consistency, market inefficiency, specialisation, bottom-up analysis and disavowal of market timing.
#6 Advent International
Advent International is a global private equity firm focusing on buyouts and growth equity investments across five core sectors: business and financial services, healthcare, industrial, technology, and retail/consumer.